Key Findings
- Across 19,238 prostate cancers profiled by Caris, HER3-high tumors were associated with luminal androgen receptor-dependent biology, an immune-cold phenotype, and improved survival in metastatic and castration-resistant disease.
- This study highlights how comprehensive molecular profiling can uncover clinically relevant molecular subgroups, prognostic biomarkers, and therapeutic targets across diverse tumor types, supporting more precise biomarkerdriven research and treatment strategies.